Tissue distribution of adriamycin-loaded chitosan nanoparticles surface-modified with glycyrrhizin in mice

Abstract

Abstract: AIM: To study the distribution characteristics and liver targeting trend of adriamycin-loaded chitosan nanoparticles surfacemodified with glycyrrhizin (GL-ADM-NPs) in mice.METHODS: The GL-ADM-NPs, adriamy cin-loaded chitosan nanoparticles (ADMNPs), and free adriamycin solution (F-ADM) were intravenously administered to mice, respectively.The LC/MS/MS method was used to determine the concentrations of Adriamycin in mice plasma, heart, liver, spleen, lung and kidney. The targeting efficiency was evaluated by targeting parameters (Re and Ce).RESULTS: Compared with F-ADM, ADM-NPs obviously increased the adriamycin concentration in the liver, Re and Ce were 3.54 and 2.2, respectively. After modified with glycyrrhizin on the nanoparticle surface, G L-ADM-NPs showed a higher targeting efficiency in the liver.The Re and Ce were 5.83 and 3.42, respectively.The levels of GL-ADM-N Ps in the heart and kidney tissues were sig nificantly decreased. The AUC were 43.06 % and 62.58 % of the values of F-ADM. CONCLUSION: GL-ADM-NPs changes the tissue distribution of ADM, has the liver targeting effect, and might decrease the side effects of ADM.It will be a promising carrier to deliver ADM to liver.

Key words: Adriamycin, Nanoparticles, Tissue Distribution, Targeting

CLC Number:

R965.2

LIU Yi-ming, LIN Ai-hua, DENG Shi-gui, WU Zhi-feng, OU Run-mei. Tissue distribution of adriamycin-loaded chitosan nanoparticles surface-modified with glycyrrhizin in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 66-71.

References

[1] Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J]. J Control Release, 2004, l00(1):5-28.
[2] Aktas Y, Andrieux K, Alonso MJ, et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspaseinhibitor [J]. Int J Pharm, 2005, 298(2):378-383.
[3] Tsuji H, Osaka S, Kiwada H. Targeting of liposomes surface-modified with glycyrrhizin to the liver. I. Preparation and biological disposition [J]. Chem Pharm T Bull (Tokyo), 1991, 39(4):1004-1008.
[4] Il'icheva TN, Proniaeva TR, Smetannikov AA, etal. Content of progesterone, glucocorticoid and glycyrrhizic acid receptors in nonnal and tumoral human breast tissue[J]. Vopr Onkol, 1998, 44(4):390-394.
[5] 黄羽, 林爱华, 张娴, 等. 甘草酸表面修饰壳聚糖纳米粒体外对肝实质细胞的靶向结合作用[J]. 中药新药与临床药理, 2008, 19(6):495-498.
[6] 许向阳, 周建平, 李玲, 等. 多柔比星壳聚糖聚合物胶束的制备及其在小鼠体内的组织分布[J]. 药学学报, 2008, 43(7):743-748.
[7] 林爱华, 刘奕明, 平其能. 甘草酸表面修饰阿霉素壳聚糖纳米粒的制备及特性研究[J]. 中国药科大学学报, 2007, 38(6):507-511.
[8] 刘奕明, 林爱华, 邓时贵, 等. 液相色谱-串联质谱法测定兔血浆阿霉素浓度[J]. 药物分析杂志, 2009, 29(8):1282-1286.
[9] 霍美蓉, 周建平, 魏彦, 等. 紫杉醇壳聚糖聚合物胶束的制备及表面电荷对其在小鼠体内组织分布的影响[J]. 药学学报, 2006, 41(9):867-872.
[10] 霍美蓉, 周建平, 魏彦, 等. 紫杉醇阳离子壳聚糖胶束的制备及其在小鼠体内组织分布[J]. 中国药科大学学报, 2006, 37(2):132-136.
[11] 郭家彬, 陈立娟, 闫长会, 等. 硫酸锌诱导金属硫蛋白对阿霉素致心脏氧自由基产生的影响[J]. 中国临床药理学与治疗学, 2006, 11(7):725-728.

[1]	CHEN Yetao, HE Junyu, WU Mengyao, WAN Fangzhu, HE Haibo, TANG Hongbo. Study on PLGA-based nanoparticles in gynecological diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 455-462.
[2]	GUO Lu, ZHONG Zhendong, HAN Yicen, SHI Yi, YANG Yong, BIAN Yuan, LIU Xiaoshu, ZHANG Jing, LANG Qin, ZHONG Tian. Effects of different administration methods on the pharmacokinetics and tissue distribution of ribavirin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 25-32.
[3]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
[4]	PAN Zhanhe, WANG Xin, SU An, ZHANG Peng, JI Haonan, WANG Xiaomei. Mechanism of celecoxib reverses adriamycin resistance in NK/T cell lymphoma cells by Notch 1/NF-κB/STAT3 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1330-1336.
[5]	WANG Weilu, MAO Yicheng, ZHU Yizhun. Research progress of autophagy in viral pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1315-1320.
[6]	CHEN Aiying, CHENG Min, MIAO Yunping, YE Xiaodi, TIAN Xuejun, ZHENG Gaoli. Pharmacokinetics and tissue distribution characteristics of sunitinib#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1105-1110.
[7]	GAO Jingshu, WANG Yu, QIN Huichao, ZHU Mengyi, WU Xiaoke. Strategy on improving quality of study of triazavirin for 2019 novel coronary pneumonia (COVID-19) with features of "core data targeted" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1171-1177.
[8]	XING Han, NING Chen, KONG Dexuan, CAI Hui, ZHOU Shiyu, REN Chang, KONG Ying, CHENG Yujie, CHEN Xijing. Tissue distribution and excretion study of GL-V9 in rats, a wogonin derivative with significant antitumor activity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 889-895.
[9]	WANG Kaiyang, LI Xiaoli, CAI Yongqing. Research progress of endoplasmic reticulum stress in heart diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1310-1314.
[10]	XU Lihua, XU Xiaoyang, XU Junjun, YU Wenying. Research progress of surface modified albumin nanoparticles in tumor targeting therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 948-954.
[11]	YUAN Yawen, LI Yan, YANG Jin. Development and validation of a sensitive LC-MS/MS method for the determination of para-aminosalicylic acid in different tissues in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 272-280.
[12]	CHEN Fangjun, WANG Zeng, CAI Xinjun, CAO Yingying, CHEN Pei, SHAO Yun. Anti-tumor effects of zoledronic acid-loaded stealth cationic liposome by targeting tumor angiogenesis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 33-36.
[13]	SHEN Qun-shan, HUANG Hou-bao, PAN Cai-ming, XUE Jun, CAI Zhang-yu, WANG Xiao, JIANG Shu-chuan. Prevention effect of 4-HPR on bladder tumor in SD rats: An in vivo experiment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 972-977.
[14]	YANG Yan-lang^1,2, ZOU He-qun¹, ZHANG Dao-you², WANG Yu-wei², LI Fan-xia², GAO Chao-qing², XU Hai-hong², CHENG Xiao-mei². Renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 381-386.
[15]	ZHAO Wen-ying, CHEN Dong-yun, XING Wen, WU Ming , YANG Zhi-min, JI Zhao-ning. Primary exploration on the protective effect of phosphocreatine sodium on adriamycin-induced cardiotoxicity in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 259-262.